तुलना करने के लिए मीट्रिक्स | POLB | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPOLBपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −8.4x | −1.8x | −0.2x | |
PEG अनुपात | −0.26 | −0.01 | 0.00 | |
क़ीमत/बुक | 6.8x | 1.7x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 1.5x | 2.8x | |
अपसाइड (विश्लेषक लक्ष्य) | 219.9% | 142.5% | 60.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 16.1% | 7.8% | अनलॉक करें |
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.